Search

Background and Aim: Measuring the prevalence of doping in recreational sport is difficult. However, to fit their initiatives, National Anti-Doping Organizations are interested in knowing the numbers, so their scarce resources are not wasted. The present study aimed to estimate the prevalence of doping and over-the-counter medicine use for performance enhancement among recreational athletes in eight European countries. Design: A survey covering + 200 sports aimed at recreational athletes 15 years and older was distributed via social media to sports clubs and individuals in eight European countries. To overcome social desirability bias, we applied indirect questioning by using the Randomized Response Technique and asked for the use of over-the-counter medicine and doping for the year 2019. Results: The prevalence of the use of over-the-counter medications for performance enhancement was estimated at 10.4%. We differentiated between the concept of "doping" as the behavior to enhance performance in a certain sport and the concept of "a doper" as a property of a person. The prevalence of dopers in recreational sport was found to be 0.4%, with 3.1% male and 0% female dopers. Responses were separated into four categories: "Artistic sports," "Combat sports," "Games," and "CGS sports" (i.e., sports measured in centimeters, grams, and seconds). The overall prevalence of doping in recreational sports was found to be 1.6%, and the results from Artistic and CGS sports did not differ significantly from this. However, in Games we found an estimated doping prevalence of 6.9%. Discussion: The estimates for the prevalence of dopers and doping in this study do not equal Anti-Doping Rule Violations as stipulated by the World Anti-Doping Agency. Still, while doping is not absent in recreational sport in Europe, it appears to be a low frequent phenomenon. Also, the differences in doping prevalence between the sports categories might reflect structural and competition-related differences, rather than differences in the logic of the sporting competition or discipline-related subcultures. Conclusion: While few recreational athletes appear to use illegal drugs to enhance performance, those who do use them are more often men than women. Yet, 1 in 10 recreational athletes uses over-the-counter medication for performance enhancement and more than 4 out of 10 use medication for other reasons than performance enhancement when doing sports. The highest doping prevalence was found in the sub-category of Games, which can likely be attributed to competition-related differences between the categories. Therefore, research on doping in recreational sports needs tailored approaches to come to a better understanding of the phenomenon. [ABSTRACT FROM AUTHOR]

This study examined the extent to which a "trigger event" in European sports altered coverage of doping in United States newspapers. Specifically, the study analyzed references to human growth hormone (hGH) before and after English rugby player Terry Newton became the first athlete to test positive for hGH. The research observed increases in hGH references following an announcement that Newton had tested positive and would receive a two-year ban from competition. [ABSTRACT FROM AUTHOR]

Objectives The main goal of this research focused on the development and validation of three instruments designed to assess athletes' self-regulatory efficacy in team contexts, team collective efficacy and team moral disengagement with relevance for doping use across three European countries. Design The research relied on three distinct studies. A first qualitative study focused on item development. The second study assessed the factor structure and internal reliability of each of the new team instruments. The third study provided evidence for instrument validity by assessing the hypothesis that efficacy measures and moral disengagement would contribute to team athletes' doping intentions. The latter two studies also focused on the relations among measures and on measurement reliability, both within and across countries. Method The first study relied on focus group data collected from twenty-one team sport professionals (mean age = 34; SD = 11.65). Four hundred and fourteen adolescent athletes (mean age = 16.69; SD = 1.55) participated in the second study, whereas seven hundred forty-nine adolescent team athletes (mean age = 16.43; SD = 1.69) participated in the third study. For the latter two studies, team athletes were recruited across Italy, Germany and Greece and provided data on the new team measures. Only athletes participating in the third study provided data on doping intentions. Results The findings of the three studies supported the empirical goals of the investigation and provided evidence for the factor structure, reliability and validity of the team instruments. Furthermore, multi-group findings supported the hypothesis that the new instruments would have equivalent measurement and validity characteristics across the three European countries. The conclusions focus on the conceptual and practical implications of these findings. [ABSTRACT FROM AUTHOR]

The term 'athlete's heart' refers to a clinical picture characterized by a slow heart rate and enlargement of the heart. A multi-modality imaging approach to the athlete's heart aims to differentiate physiological changes due to intensive training in the athlete's heart from serious cardiac diseases with similar morphological features. Imaging assessment of the athlete's heart should begin with a thorough echocardiographic examination. Left ventricular (LV) wall thickness by echocardiography can contribute to the distinction between athlete's LV hypertrophy and hypertrophic cardiomyopathy (HCM). LV end-diastolic diameter becomes larger (> 55 mm) than the normal limits only in end-stage H CM patients when the LV ejection fraction is,50%. Patients with HCM also show early impairment of LV diastolic function, whereas athletes have normal diastolic function. When echocardiography cannot provide a clear differential diagnosis, cardiac magnetic resonance (CMR) imaging should be performed. With CMR, accurate morphological and functional assessment can be made. Tissue characterization by late gadolinium enhancement may show a distinctive, non-ischaemic pattern in HCM and a variety of other myocardial conditions such as idiopathic dilated cardiomyopathy or myocarditis. The work-up of athletes with suspected coronary artery disease should start with an exercise ECG. In athletes with inconclusive exercise ECG results, exercise stress echocardiography should be considered. Nuclear cardiology techniques, coronary cardiac tomography (CCT) and/or CMR may be performed in selected cas es. Owing to radiation exposure and theyoung age of most athletes, the use of CCT and nuclear cardiology techniques should be restricted to athletes with unclear stress echocardiography or CMR. [ABSTRACT FROM AUTHOR]

Socioeconomic differences between countries, including corruption and doping scandals, have increased in the last few decades. The aims of the current investigation were to examine doping prevalence according to world areas and sport groups and its association with socioeconomic factors worldwide. The Anti-Doping Rule Violations (ADRVs) of 160 countries competing at 2016 Olympics were analyzed between 2013 and 2018. In addition, the relationship between doping prevalence and socioeconomic characteristics, including Human Development Index (HDI), Per Capita Income (PCI) and Corruption Index (CI), was investigated. Africa, Asia, and America were revealed to have a significantly lower doping prevalence than Europe and Oceania when observing the sum and the mean ADRV/10,000 inhabitants (p < 0.01). Strong to moderate correlations were identified between Corruption Index and ADRVs and HDI and ADRVs (p < 0.01). However, the number of Olympic athletes was positively associated with the ADRVs and the HDI (r = 0.663 and 0.424, respectively). In the comparison by sport groups, the Independent Recognized Sports (AIMS) showed significantly higher Adverse Analytical Findings (AAF) and ADRVs (p < 0.01) than Olympic and Recognized International Sports (ARISF). In conclusion, the results of the current study reveal doping prevalence differences between world areas and sport categories, identifying associations with socioeconomic characteristics of each country.

The article focuses on the prevalence of sports betting in the Europe. It informs that sports in the Europe is facing a number of threats and challenges like doping, corruption and money laundering. It informs about the general regulatory framework of sport betting in major European nations such as Great Britain, Canada and Italy. It also reflects on different types of sports betting.

The article offers news briefs related to sports in Europe. The International Sport and Culture Association (ISCA) has launched the EuroVolNet project related to the voluntary activities in sports. The World Health Organization (WHO) has established the Global Recommendations on Physical Activity for Health. The European Commission (EC) has awarded a research grant to the European Health and Fitness Association (EHFA) to look after physical fitness against a doping project .

In Europe, chemical castration has been adopted as a treatment for paraphilia since the 1930s. Among the various chemical castration agents, luteinizing hormone-releasing hormone (LHRH) agonists are now used widely because of their effectiveness and safety. In South Korea, a legislation of chemical castration to control the sexual impulses of sexual offenders was enforced in July 2011. Most of these subjects are treated with leuprorelin acetate, an LHRH agonist, for chemical castration. Despite this, there are few studies that address the long-term influence of LHRH agonists on testosterone (T) and epitestosterone (E) levels in chemical castration subjects. In order to analyze the urinary levels of T in chemical castration subjects, whose T levels are extremely low, we developed and validated an analytical method for the detection of both T and E in human urine using a liquid chromatography-tandem mass spectrometry (LC-MS/MS) system. The urine samples were hydrolyzed, extracted, and analyzed by LC-MS/MS with electrospray ionization in the positive-ion mode. The limits of detection were 0.02 ng/mL and the limits of quantitation were 0.05 ng/mL, which provided great sensitivity. The established method was applied to urine samples from chemical castration subjects and healthy male volunteers. The chemical castration subjects showed significantly lower urinary T levels than the control subjects. In addition, the urinary E levels were also lower in the chemical castration subjects; however, the T/E ratios were constant and did not show a notable decrease because of the simultaneous decrease in both urinary T and E. The urinary T levels and T/E ratio did not exceed the doping control criteria for exogenous T ingestion for any subject. This study shows the trend of urinary T and E levels in long-term treated chemical castration subjects by establishing a highly sensitive LC-MS/MS method, that provides useful information for monitoring chemical castration., (© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.)

The article discusses several research on medical topics published in different journals. Topics of the studies include massive pneumomediastinum in a male patient recovering from non-traumatic acute respiratory distress syndrome, risk of myocardial infarction on days in the highest and lowest tertile of total pollen concentrations, detection of meldonium in athlete urine samples, and perioperative complications in children before and after implementation of the surgical checklist in Canada.

Big sports events like the 2008 European Football Championship are a challenge for anti-doping activities, particularly when the sports event is hosted by two different countries and there are two laboratories accredited by the World Anti-Doping Agency. This challenges the logistics of sample collection as well as the chemical analyses, which must be carried out timeously. The following paper discusses the handling of whereabouts information for each athlete and the therapeutic use exemption system, experiences in sample collection and transportation of blood and urine samples, and the results of the chemical analysis in two different accredited laboratories. An overview of the analytical results of blood profiling and growth hormone testing in comparison with the distribution of the normal population is also presented., (Copyright (c) 2010 John Wiley & Sons, Ltd.)

The IOC recognised growth hormone (GH) as a drug of abuse in 1992 and recruited me as an expert to advise them on the development of a test to detect its abuse. After a long gestation period where the IOC gradually changed their attitude to research they co-funded the GH-2000 project with the European Union (EU). GH-2000 was a unique consortium of Europe's best endocrinologists and scientists in partnership with two GH manufacturers and the IOC with a greater than two million dollar budget. GH-2000 selected a method based on the measurement of GH-dependent markers and selected IGF-I and P-III-P as the most suitable markers and demonstrated that they could detect 100% of men taking GH with a false-positive rate better than 1:10,000; sensitivity was reduced however in women. GH-2000 reported back to EU and IOC in January 1999 in time to have the test available for the 2000 Olympic Games. Results were quality assured by an expert workshop. Politics has prevented this from happening however, some reasons are discussed as to why 9 years later it still has not been introduced.

Growth hormone is abused by athletes for its anabolic and lipolytic properties. The detection of GH abuse is challenging because it is an endogenous hormone whose concentration varies widely in any one day. The GH-2000 project proposed a test based on the measurement of IGF-I and type III pro-collagen (P-III-P). When the results of the GH-2000 project were presented to an expert workshop, the method was supported but it was felt that several issues needed to be resolved before the method could be adopted. The first was a potential effect of ethnicity as most subjects in the GH-2000 were white Europeans and the second was a possible effect of injury as P-III-P is a marker of soft tissue turnover. The GH-2004 project was conceived to address these concerns. The GH-2004 project has shown that while there are minor differences in IGF-I and P-III-P between ethnicities, these are small and do not affect the performance of the test. Injury leads to a small rise in P-III-P but again this is not of sufficient magnitude to affect the performance of the test. The GH-2004 project has provided further support for the marker approach as a means of detecting GH abuse in athletes. As WADA have not developed their own immunoassays, however, further work is needed to validate newer commercial assays measuring IGF-I and P-III-P to establish reliable conversion factors to the original GH-2000 units to allow the published formulae to be used.

One million individuals in the United States alone are estimated to be current or past users of anabolic-androgenic steroids. In the United States fifty-percent of anabolic-androgenic steroid users administer their compounds intramuscularly, and twenty-five percent of adolescent anabolic-androgenic steroid users share needles, placing these young adults at risk for infections related to injection. To examine the medical literature for reports of infections attributable to anabolic-androgenic steroids, we conducted a MEDLINE (1966-1998) and AIDSLINE (1980-1998) world literature review to examine all references that attributed infections to anabolic-androgenic steroid injection. Infections associated with anabolic-androgenic steroid injection include three cases of HIV, one case of hepatitis B, one case of hepatitis C, eight abscesses, and a case of fungal endophthalmitis. No cross-sectional or prospective studies exist that document the risk of infections related to anabolic-androgenic steroid injection. These serious infectious complications of anabolic-androgenic steroid injection may be avoided with education and prevention techniques. Infections occurring in anabolic-androgenic steroid users are not as common as in intravenous drug users.